Non-motor dysfunction in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 6, 2007, Pages 323-332

  Ziemssen, Tjalf ^a   Reichmann, Heinz ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Behavioural disorders; Dysautonomia; Non motor dysfunction; Olfactory dysfunction; Parkinson's disease; Sleep disorders

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GALANTAMINE; LEVODOPA; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PRAMIPEXOLE; REBOXETINE; ROPINIROLE; SELEGILINE;

BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DYSAUTONOMIA; HUMAN; HYPOSMIA; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SMELLING DISORDER; UNSPECIFIED SIDE EFFECT;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; DEPRESSIVE DISORDER; HUMANS; OLFACTION DISORDERS; PARKINSON DISEASE; SLEEP DISORDERS;

EID: 34547683268     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.12.014     Document Type: Review

References (70)

1. Hughes A.J., Ben-Shlomo Y., Daniel S.E., and Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology 42 (1993) 1142-1146
2. Parkinson J. An essay in the shaking palsy (1817), Sherwood, Neely, and Jones, London
3. Braak H., DelTredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-210
4. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., and Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992) 138-142
5. Müller A., Müngersdorf M., Reichmann H., Strehle G., and Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 9 (2002) 521-524
6. Abele M., Riet A., Hummel T., Klockgether T., and Wüllner U. Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. J Neurol 250 (2003) 1453-1455
7. Sommer U., Hummel T., Cormann K., Müller A., Frasnelli J., Kropp J., et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19 (2004) 1196-1202
8. Becker G., Seufert J., Bogdahn U., Reichmann H., and Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45 (1995) 182-184
9. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.I., Wolters E.Ch., and Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56 (2004) 173-181
10. Stiasny-Kolster K., Doerr Y., Möller J.C., Hoffken H., Behr T.M., Oertel W.H., et al. Combination of idiopathic REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 Part 1 (2005) 126-137
11. Hummel T., Jahnke U., Sommer U., Reichmann H., and Müller A. Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm 112 (2005) 669-676
12. Aarsland D., Tandberg E., Larssen J.P., and Cummings J.L. Frequency of dementia in Parkinson's disease. Arch Neurol 53 (1996) 538-542
13. Riedel O., Dodel R., Spottke A., Deuschl G., Förstl H., Henn F., et al. Wie beurteilen Ärzte die Häufigkeit demenzieller, depressiver und psychotischer Syndrome bei Patienten mit Parkinsonerkrankungen?-Eine Befragung von 500 Fachärzten im ambulanten Versorgungssektor Deutschlands. Akt Neurol 33 (2006) 374-380
14. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60 (2003) 387-392
15. Emre M. Demetia associated with Parkinson's disease. Lancet Neurol 2 (2003) 229-237
16. Cummings J.L. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1 (1988) 24-36
17. Bum D.J., and McKeith I.G. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 20 Suppl. 6 (2003) 72-79
18. Perry E.K., Irving D., Kerwin J.M., McKeith I.G., Thompson P., Collerton D., et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7 (1993) 69-79
19. Jellinger K.A. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm 56 Suppl. (1999) 1-29
20. Ballard C., Ziabreva I., Perry R., Larsen J.P., O'Brien J., McKeith I., et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 (2006) 1931-1934
21. Alves G., Larsen J.P., Emre M., Wentzel-Larsen T., and Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 21 (2006) 1123-1130
22. Burn D.J., Rowan E.N., Allan L.M., Molloy S., O'Brien J.T., and McKeith I.G. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Neurol Neurosurg Psychiatry 77 (2006) 585-589
23. Aarsland D., and Hutchinson M. Galantamine for Parkinson's disease with dementia. Eur Neuropsychopharm 12 Suppl. 12 (2002) S378-S379
24. Müller T., Welnic J., Fuchs G., Baas H., Ebersbach G., and Reichmann H. Donepezil is effective in patients with Parkinson's disease with dementia. J Neural Transm 71 Suppl. (2006) 27-30
25. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2005) 2509-2518
26. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry 149 (1992) 443-454
27. Burn D.J. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 17 (2002) 445-454
28. Fukunishi I., Hosokawa K., and Ozaki S. Depression antedating the onset of Parkinson's disease. Jpn J Psychiatry Neurol 45 (1991) 7-11
29. Lemke M.R., Fuchs G., Gemende I., Herting B., Oehlwein C., Reichmann H., et al. Depression and Parkinson's disease. J Neurol 251 Suppl. 6 (2004) VI/24-VI/27
30. Funkiewiez A., Ardouin C., Caputo E., Krack P., Fraix V., Klinger H., et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (2004) 834-839
31. Tandberg E., Larsen J.P., Aarsland D., and Cummings J.L. The occurrence of depression in Parkinson's disease. A community based study. Arch Neurol 53 (1996) 175-179
32. Andersen J., Aabro E., Gulmann N., Hjelmsted A., and Pedersen H.E. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 62 (1980) 210-219
33. Ceravolo R., Nuti A., Piccinni A., Dell'Agnello G., Bellini G., Gambaccini G., et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55 (2000) 1216-1218
34. Tesei S., Antonini A., Canesi M., Zecchinelli A., Mariani C.B., and Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 15 (2000) 986-989
35. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11 (2000) 58-65
36. Reichmann H., Brecht M.H., Koster J., Kraus P.H., and Lemke M.R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17 (2003) 965-973
37. Rektorova I., Rektor I., Bares M., Dostal V., Ehler E., Fanfrdlova Z., et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10 (2003) 399-406
38. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161 (2004) 564-566
39. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 4 (2002) 307-314
40. Perugi C., Toni C., Ruffolo G., Frare F., and Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 34 (2001) 137-141
41. Ziemssen T., Schmidt C., Herting B., and Reichmann H. Autonomic dysfunction in Parkinson's Disease and MSA. Akt Neurol 33 (2006) 385-393
42. 123I]MIBG separates Parkinson's disease from multi system atrophy. Neurology 53 (1999) 1020-1025
43. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2 (2003) 669-675
44. Mathias C.J. Cardiovascular autonomic function in parkinsonian patients. Clin Neurosci 5 (1998) 153-166
45. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2 (2003) 107-116
46. Eady M.J., and Tyrer J.H. Alimentary disorder on parkinsonism. Austral Ann Med 14 (1965) 13-22
47. Edwards L., Quigley E.M.M., Hofman R., and Pfeiffer T.F. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 8 (1993) 83-86
48. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., et al. Frequency of bowel movements and future risk of Parkinson's disease. Neurology 57 (2001) 456-462
49. Stocchi F., Badiali D., Vacca L., D'Alba L., Bracci F., Ruggieri S., et al. Anorectal function in MSA and Parkinson's disease. Mov Disord 15 (2000) 71-76
50. Fowler C.J. Urinary disorders in Parkinson's disease and multiple system atrophy. Funct Neurol 16 (2001) 277-282
51. Wermuth L., and Stenager E. Sexual problems in young patients with Parkinson's disease. Acta Neurol Scand 91 (1995) 453-455
52. Mano Y., Nakamuro T., Takayanagi T., and Mayer R.F. Sweat function in Parkinson's disease. J Neurol 241 (1994) 573-576
53. Goetz C.G., Lutge W., and Tanner C.M. Autonomic dysfunction in Parkinson's disease. Neurology 36 (1986) 73-75
54. Taly A.B., and Muthane U.B. Involvement of peripheral nervous system in juvenile Parkinson's disease. Acta Neurol Scand 85 (1992) 272-275
55. Appenzeller O., and Goss J.E. Autonomic deficits in Parkinson's syndrome. Arch Neurol 24 (1971) 50-57
56. Comella C.L. Sleep and Parkinson's disease. In: Adler C.H., and Ahlskog J.E. (Eds). Parkinson's disease and movement disorders: diagnostic and treatment guidelines for the practicing physician (2000), Humana Press, Totowa 151-160
57. Commella C.L. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 3 (2003) 173-180
58. Askenasy J.J., and Yahr M.D. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study. Neurology 35 (1985) 527-532
59. Hogl B.E., Gomez-Arevalo G., Garcia S., Scipioni O., Rubio M., Blanco M., et al. A clinical, pharmacologic and polysomnographic study of sleep benefit in Parkinson's disease. Neurology 50 (1998) 1332-1339
60. Poewe W., and Hogl B.E. Parkinson's disease and sleep. Curr Opin Neurol 13 (2000) 423-426
61. Friedman A. Sleep pattern in Parkinson's disease. Acta Med Pol 21 (1980) 193-199
62. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002) 1019-1024
63. Hobson D.E., Lang A.E., Martin W.R.W., Razmy A., Rivest J., and Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement disorders group. JAMA 287 (2002) 455-463
64. Roth T., Rye D.B., Borchert L.D., Bartlett C., Bliwise D.L., Cantor C., et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 4 (2003) 275-280
65. Gjerstad M.D., Alves G., Wentzel-Larsen T., Aarsland D., and Larsen J.P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. Neurology 67 (2006) 853-858
66. Boeve B.F., Silber M.H., Parisi J.E., Dickson D.W., Ferman T.J., Benarroch E.E., et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61 (2003) 40-45
67. Gagnon J., Bedard M., Fantini M.L., Petit D., Panisset M., Rompre S., et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 59 (2002) 585-589
68. Ondo W.G., Vuong K.D., and Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59 (2002) 421-424
69. Krishnan P.R., Bhatia M., and Behari M. Restless legs syndrome in Parkinson's disease. Mov Disord 18 (2003) 181-185
70. Carlucci C.M., and Hauser R.A. Sleep apnea. In: Pfeiffer R.F., and Bodis-Wollner I. (Eds). Parkinson's disease and nonmotor dysfunction (2005), Humana Press, Totowa 209-220